AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

Phase 1

Completed

Conditions: Bioavailability
B-cell Lymphoid Cancer

Interventions: Drug: Treatment A- Part 1
Drug: Treatment A-Part 2
Drug: Treatment B- Part 1
Drug: Treatment B - Part 2
Drug: Treatment C - Part 1
Drug: Treatment C - Part 2
Drug: Treatment D - Part 2
Drug: Treatment D- Part 1

First Posted Date: 2020-07-27

Last Posted Date: 2021-02-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 54

Registration Number: NCT04488016

Locations: 🇺🇸
Research Site, Baltimore, Maryland, United States

Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children

Phase 2

Completed

Conditions: RSV Infection

Interventions: Drug: Nirsevimab

First Posted Date: 2020-07-24

Last Posted Date: 2023-11-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 100

Registration Number: NCT04484935

Locations: 🇬🇧
Research Site, Nottingham, United Kingdom

A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients

Phase 1

Completed

Conditions: Non-alcoholic Steatohepatitis (NASH)

Interventions: Drug: AZD2693
Other: Placebo

First Posted Date: 2020-07-23

Last Posted Date: 2024-01-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 74

Registration Number: NCT04483947

Locations: 🇺🇸
Research Site, San Antonio, Texas, United States

HF Prevalence and Evolution of HF in DM II Patients at High Risk

Completed

Conditions: RELATED REGISTRY SEARCH

First Posted Date: 2020-07-22

Last Posted Date: 2025-01-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 244

Registration Number: NCT04482283

Locations: 🇬🇷
Research Site, Thessaloniki, Greece

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

Phase 2

Recruiting

Conditions: Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer
Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer

Interventions: Drug: Trastuzumab deruxtecan

First Posted Date: 2020-07-22

Last Posted Date: 2025-06-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 468

Registration Number: NCT04482309

Locations: 🇬🇧
Research Site, Sutton, United Kingdom

Evaluation of AZD8154 Concentrations in Blood

Phase 1

Terminated

Conditions: Asthma

Interventions: Drug: AZD8154 Monodose DPI presented in capsules
Drug: AZD8154 nebuliser
Drug: AZD8154 Placebo Monodose DPI presented in capsules

First Posted Date: 2020-07-21

Last Posted Date: 2021-08-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 10

Registration Number: NCT04480879

Locations: 🇩🇪
Research Site, Berlin, Germany

A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer/DDI Study

Interventions: Drug: AZD4635
Drug: Fluvoxamine

First Posted Date: 2020-07-20

Last Posted Date: 2021-01-06

Lead Sponsor: AstraZeneca

Target Recruit Count: 28

Registration Number: NCT04478513

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: AZD9977

First Posted Date: 2020-07-14

Last Posted Date: 2022-03-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 18

Registration Number: NCT04469907

Locations: 🇺🇸
Research Site, Blue Ash, Ohio, United States

Assessment of Hyperkalemia's Illness and Treatment Burden in Chronic Kidney Disease and Heart Failure Patients: HK Registry Pilot Study

Completed

Conditions: Hyperkalemia

First Posted Date: 2020-07-10

Last Posted Date: 2021-09-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 146

Registration Number: NCT04466969

Locations: 🇯🇵
Research Site, Tsuchiurashi, Ibaraki, Japan

Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours

Phase 1

Completed

Conditions: Advanced Solid Tumours

Interventions: Drug: Adavosertib (AZD1775)

First Posted Date: 2020-07-08

Last Posted Date: 2022-07-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 6

Registration Number: NCT04462952

Locations: 🇯🇵
Research Site, Chuo-ku, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy